MicroRNA-150 as a Potential Biomarker in Diagnosis of Cancer: a Meta-Analysis

Clinical Laboratory
|August 10, 2017
PubMed
Abstract

Insights

MicroRNA (miR)-150 shows potential as a noninvasive biomarker for various cancers. This meta-analysis confirms its diagnostic value, with high sensitivity and specificity for cancer detection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • MicroRNAs (miRNAs) play a role in human cancer development.
  • Previous research on circulating miR-150 levels and cancer risk yielded inconsistent results.

Purpose of the Study:

  • To evaluate the diagnostic accuracy of miR-150 as a biomarker for human cancers.
  • To consolidate existing evidence through a meta-analysis.

Main Methods:

  • A systematic literature search was conducted across PubMed, Embase, and Web of Science.
  • Keywords used included "miR-150" and "human cancer".
  • Diagnostic value was assessed using pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the curve (AUC).

Main Results:

  • The meta-analysis demonstrated a pooled sensitivity of 80% and specificity of 81% for miR-150.
  • The diagnostic odds ratio (DOR) was 16.47.
  • The area under the curve (AUC) was 0.86, indicating good diagnostic performance.

Conclusions:

  • Circulating miR-150 shows promise as a noninvasive tumor marker for multiple human cancers.
  • Further large-scale studies are warranted to validate these findings.